It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Understanding and treating heterogeneous brain disorders requires specialized techniques spanning genetics, proteomics, and neuroimaging. Designed to meet this need, NeuroPM-box is a user-friendly, open-access, multi-tool cross-platform software capable of characterizing multiscale and multifactorial neuropathological mechanisms. Using advanced analytical modeling for molecular, histopathological, brain-imaging and/or clinical evaluations, this framework has multiple applications, validated here with synthetic (N > 2900), in-vivo (N = 911) and post-mortem (N = 736) neurodegenerative data, and including the ability to characterize: (i) the series of sequential states (genetic, histopathological, imaging or clinical alterations) covering decades of disease progression, (ii) concurrent intra-brain spreading of pathological factors (e.g., amyloid, tau and alpha-synuclein proteins), (iii) synergistic interactions between multiple biological factors (e.g., toxic tau effects on brain atrophy), and (iv) biologically-defined patient stratification based on disease heterogeneity and/or therapeutic needs. This freely available toolbox (neuropm-lab.com/neuropm-box.html) could contribute significantly to a better understanding of complex brain processes and accelerating the implementation of Precision Medicine in Neurology.
Iturria-Medina et al. demonstrate the validation of NeuroPM-box — an open-access, multi-tool cross-platform software that can characterize multiscale and multifactorial neuropathological mechanisms. Their tool potentially contributes to a better understanding of complex brain processes, which could accelerate the implementation of Precision Medicine.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details

1 Montreal Neurological Institute, Neurology and Neurosurgery Department, Montreal, Canada (GRID:grid.416102.0) (ISNI:0000 0004 0646 3639); Montreal Neurological Institute, McConnell Brain Imaging Centre, Montreal, Canada (GRID:grid.416102.0) (ISNI:0000 0004 0646 3639); Ludmer Centre for Neuroinformatics & Mental Health, Montreal, Canada (GRID:grid.416102.0)
2 Biospective Inc., Montreal, Canada (GRID:grid.416102.0)